Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Fibroblast growth factor 23–Fibroblast growth factor receptor 1 (FGF23–FGFR1) complex is a ternary signaling assembly essential for maintaining systemic phosphate homeostasis and vitamin D metabolism (UniProt Q9GZV9, P11362). The complex is formed when the bone-derived hormone FGF23 binds to the FGFR1c isoform in the presence of the transmembrane protein alpha-Klotho, which acts as an essential co-receptor to increase the affinity of FGF23 for the receptor (PMID: 17086192). Once assembled, the complex activates the MAPK/ERK signaling pathway in the renal proximal tubules, leading to the downregulation of sodium-phosphate cotransporters and the suppression of active vitamin D synthesis (PMID: 29343898). Pathological overproduction of FGF23 leads to excessive signaling through this complex, resulting in phosphate wasting diseases such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) (NIH/GARD). Conversely, deficient signaling or FGF23 resistance can lead to hyperphosphatemic familial tumoral calcinosis (PubMed: 16415873). Therapeutic targeting of this complex is clinically validated by Burosumab, a monoclonal antibody that binds to FGF23 and prevents its interaction with the FGFR1-Klotho complex, thereby restoring normal phosphate levels (FDA Label: Crysvita). Additionally, pan-FGFR inhibitors used in oncology, such as Erdafitinib, can inadvertently disrupt this complex, leading to hyperphosphatemia as a common side effect (PubChem CID: 67165467). Understanding the structural and functional nuances of this complex is vital for developing treatments for mineral bone disorders and managing the toxicities of FGFR-targeted cancer therapies.
Neutralization of the FGF23 ligand to prevent assembly of the signaling complex or ATP-competitive inhibition of the FGFR1 tyrosine kinase domain to block downstream signal transduction.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibroblast growth factor 23–Fibroblast growth factor receptor 1 complex (FGF23–FGFR1 complex).